Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Juvenile Huntington disease (JHD) is a form of Huntington disease (HD), characterized by onset of signs and symptoms before 20 years of age.
Biomarker and diagnostic research for juvenile Huntington disease has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
112 publications have been identified in PubMed for juvenile Huntington disease. Research spans Review / Meta-Analysis (45%), Basic Science / Preclinical (30%), and Epidemiology / Natural History (9%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 49 | 45% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 8:03 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research |
33 |
30% |
Disease patterns and progression | 10 | 9% |
Patient case studies | 5 | 5% |
Other research | 4 | 4% |
New treatment approaches | 4 | 4% |
Testing and diagnosis research | 3 | 3% |
Clinical study results | 2 | 2% |
Chan LL (2026). [PMID: 41955484](https://pubmed.ncbi.nlm.nih.gov/41955484/). *J Huntingtons Dis*. [Review / Meta-Analysis]
Bachhuber A (2026). [PMID: 41697335](https://pubmed.ncbi.nlm.nih.gov/41697335/). *Radiologie (Heidelb)*. [Review / Meta-Analysis]
Dontiboina HR (2026). [PMID: 42217109](https://pubmed.ncbi.nlm.nih.gov/42217109/). *Mol Neurobiol*. [Review / Meta-Analysis]
Donaldson J (2026). [PMID: 41233526](https://pubmed.ncbi.nlm.nih.gov/41233526/). *Nat Rev Neurol*. [Review / Meta-Analysis]
Maimon R (2026). [PMID: 41690900](https://pubmed.ncbi.nlm.nih.gov/41690900/). *Trends Mol Med*. [Review / Meta-Analysis]
Huang C (2026). [PMID: 41608623](https://pubmed.ncbi.nlm.nih.gov/41608623/). *Int J Biol Sci*. [Review / Meta-Analysis]
Gulzar M (2026). [PMID: 40874597](https://pubmed.ncbi.nlm.nih.gov/40874597/). *Neurodegener Dis Manag*. [Review / Meta-Analysis]
Woods WA (2026). [PMID: 41504917](https://pubmed.ncbi.nlm.nih.gov/41504917/). *J Neurol*. [Review / Meta-Analysis]
Cardoso F (2026). [PMID: 41612618](https://pubmed.ncbi.nlm.nih.gov/41612618/). *Brain*. [Review / Meta-Analysis]
Ishtayeh H (2026). [PMID: 41578740](https://pubmed.ncbi.nlm.nih.gov/41578740/). *Brain*. [Basic Science / Preclinical]
AI-curated news mentioning juvenile Huntington disease
Updated Sep 9, 2026
A recent study published in PubMed highlights neuroimaging findings in three patients with juvenile Huntington's disease. This research contributes to the understanding of the disease's progression and potential biomarkers.
A case report highlights missed opportunities for goals-of-care conversations in a patient with end-stage juvenile Huntington's disease. This study emphasizes the need for improved communication strategies in managing complex care for patients with rare diseases.